<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17348" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Alendronate</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wilkins Parker</surname>
            <given-names>Lyndie R.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lyndie Wilkins Parker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17348.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Alendronate is approved by the&#x000a0;U.S. Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis,&#x000a0;steroid-induced osteoporosis, and male osteoporosis, as well as for the management of Paget disease of bone.&#x000a0;Alendronate belongs to&#x000a0;the class of bisphosphonate medications, which aids in the prevention of bone resorption and the promotion of bone density, making it a valuable treatment for osteoporosis and various other bone-related conditions.&#x000a0;By binding to hydroxyapatite crystals within bone, alendronate downregulates osteoclast-mediated bone reabsorption, thereby leading to a reduction in bone matrix breakdown.&#x000a0;Both of these mechanisms collectively contribute to regulating the reabsorption and turnover of minerals. This activity provides a comprehensive review of alendronate, including its indications, mechanism of action, specific patient populations, potential adverse effects, and the significance of monitoring during its administration. This activity also highlights the essential&#x000a0;collaborative approach among&#x000a0;interprofessional healthcare professionals for the effective treatment and prevention of osteoporosis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate patient populations and conditions for which alendronate is indicated, including postmenopausal osteoporosis, steroid-induced osteoporosis, male osteoporosis, and Paget disease of bone.</p></list-item><list-item><p>Screen patients for contraindications and risk factors affecting alendronate therapy, such as esophageal abnormalities, delayed esophageal emptying, and hypocalcemia.</p></list-item><list-item><p>Apply knowledge of alendronate's mechanism of action to tailor treatment plans for specific patient needs, considering factors such as age, gender, and fracture risk.</p></list-item><list-item><p>Collaborate with other healthcare professionals to provide comprehensive education on alendronate therapy, potential adverse effects, and the importance of medication adherence for optimal patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17348&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17348">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17348.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Alendronate is approved by the&#x000a0;U.S. Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis,&#x000a0;steroid-induced osteoporosis, and male osteoporosis, as well as for the management of Paget disease of bone. Alendronate belongs to&#x000a0;the class of bisphosphonate medications, which aids in the prevention of bone resorption and the promotion of bone density, making it a valuable treatment for osteoporosis and various other bone-related conditions. Alendronate is an option for maintaining or increasing bone mass, whereas risedronate is preferred in men with osteoporosis.<xref ref-type="bibr" rid="article-17348.r1">[1]</xref>&#x000a0;</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Alendronate is used as an off-label medication for the below-mentioned conditions.</p>
        <p><bold>Crohn-induced osteoporosis:&#x000a0;</bold>Although alendronate is used as an off-label medication for&#x000a0;Crohn-induced osteoporosis, studies have shown that pamidronate infusions are the optimal treatment option for this condition.&#x000a0;Pamidronate infusions&#x000a0;can help mitigate upper gastrointestinal (GI) adverse effects associated with oral alendronate. However, current evidence underscores bisphosphonates as the preferred first-line therapy, whether administered orally or via parenteral routes.<xref ref-type="bibr" rid="article-17348.r2">[2]</xref></p>
        <p><bold>Osteopenia with cystic fibrosis:</bold> Alendronate is used as an off-label medication for treating osteopenia secondary to cystic fibrosis of the lung. However, a multicenter, randomized controlled trial in Canada with 56 participants demonstrated that alendronate therapy was well-tolerated and significantly improved bone mineral density over 12 months compared to a placebo.<xref ref-type="bibr" rid="article-17348.r3">[3]</xref> In an additional double-blinded trial, alendronate exhibited a notable increase in spine and femur bone mineral density in individuals with cystic fibrosis.<xref ref-type="bibr" rid="article-17348.r4">[4]</xref>&#x000a0;</p>
        <p><bold>Fibrous dysplasia:</bold> Alendronate is used as an off-label medication for treating fibrous dysplasia of the bone. Current data supports the utilization of pamidronate, as it demonstrates a reduction in bone remodeling, as indicated by decreased serum alkaline phosphatase and urinary hydroxyproline. However, current research does not support using alendronate for this purpose.<xref ref-type="bibr" rid="article-17348.r5">[5]</xref></p>
        <p><bold>Growth hormone deficiency:</bold> Alendronate is used as an off-label medication for managing growth hormone deficiency in individuals. In a randomized controlled trial involving adults with osteoporotic adult-onset growth hormone deficiency, adding alendronate therapy for 12 months yielded no significant differences in bone turnover, bone mineral density, or the prevalence of vertebral fractures. However, participants concurrently treated with recombinant growth hormone and alendronate demonstrated a significant reduction in bone turnover and a substantial increase in bone mineral density, specifically in the lumbar spine. Further research is required to confirm and validate these findings.<xref ref-type="bibr" rid="article-17348.r6">[6]</xref></p>
        <p><bold>Hypercalcemia of malignancy:</bold>&#x000a0;Alendronate is&#x000a0;used as an off-label medication to treat hypercalcemia of malignancy. Although, in the past, bisphosphonates were used as the primary treatment for this condition, current research demonstrates a&#x000a0;superior efficacy in intravenous calcitonin in addressing this condition.<xref ref-type="bibr" rid="article-17348.r7">[7]</xref>&#x000a0;Current clinical guidelines indicate that first-line therapy involves aggressive intravenous hydration, followed by the administration of calcitonin. Subsequently, 2 to 4 days after initiating calcitonin therapy, zoledronic acid or ibandronate is recommended. Zoledronic acid is the preferred choice over alendronate due to its superior potency. If zoledronic acid is unavailable, ibandronate or pamidronate can be considered alternative options.<xref ref-type="bibr" rid="article-17348.r8">[8]</xref></p>
        <p>Alendronate is often utilized by clinicians in the management of osteoporosis induced by male hypogonadism. A randomized controlled study involving 22 men with&#x000a0;osteoporosis and long-standing hypogonadism revealed that long-term treatment with&#x000a0;alendronate, in conjunction with testosterone replacement, increased femoral neck bone mineral density.<xref ref-type="bibr" rid="article-17348.r9">[9]</xref></p>
        <p>Rarely, alendronate is used off-label in pediatric populations to address conditions such as bone necrosis, hypervitaminosis D, and secondary amenorrhea. Due to the unknown teratogenic effects and the extended half-life of bisphosphonates, there is insufficient evidence to endorse bisphosphonate therapy for pediatric populations.<xref ref-type="bibr" rid="article-17348.r10">[10]</xref></p>
        <p>Wang et al conducted an in vitro study involving human SW1353 chondrocytes exposed to alendronate for 12 hours,&#x000a0;during which they monitored the expression of extracellular matrix&#x02013;related genes, including <italic toggle="yes">Col2&#x003b1;1</italic>, <italic toggle="yes">COL9&#x003b1;2</italic>, and <italic toggle="yes">Acan</italic>.<xref ref-type="bibr" rid="article-17348.r11">[11]</xref> Alendronate increased the expression of the extracellular matrix&#x02013;related genes by upregulating the expression of SOX-9. Notably, alendronate successfully reversed the reduction of extracellular matrix&#x02013;related genes caused by tumor necrosis factor-alpha (TNF-&#x003b1;). The study suggests that alendronate may be a promising treatment for osteoarthritis by promoting cartilage repair.</p>
      </sec>
      <sec id="article-17348.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Alendronate belongs to&#x000a0;the class of bisphosphonate medications and is used to treat osteoporosis and other bone-related conditions. By binding to hydroxyapatite crystals within bone, alendronate downregulates osteoclast-mediated bone reabsorption, thereby leading to a reduction in bone matrix breakdown.&#x000a0;Both of these mechanisms collectively contribute to regulating the reabsorption and turnover of minerals.&#x000a0;Alendronate differs from other bone-modifying supplements by its ability to suppress bone formation without modifying bone mineral accrual in endocortical or intracortical bone.<xref ref-type="bibr" rid="article-17348.r12">[12]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>The&#x000a0;pharmacokinetic profile of alendronate is provided below.</p>
        <p><bold>Bioavailability:</bold>&#x000a0;The bioavailability of alendronate is limited to 0.64% in fasting women and 0.59% in fasting men. However, this bioavailability diminishes by as much as 60% when the drug is taken with food.</p>
        <p><bold>Half-life:&#x000a0;</bold>Alendronate exhibits a notably protracted terminal half-life of approximately 10 years within bone tissues.</p>
        <p><bold>Excretion:&#x000a0;</bold>Alendronate is primarily excreted through urine, accounting for 50% of elimination, with unabsorbed drugs appearing in the feces.</p>
        <p>Kendler et al conducted a study investigating the transition from denosumab treatment to alendronate treatment and its impact on bone mineral density.<xref ref-type="bibr" rid="article-17348.r13">[13]</xref> The clinical trial included postmenopausal women who were treatment-naive, with bone mineral density T-scores ranging from -2.0 to -4.0. The study results revealed that after&#x000a0;1 year of denosumab treatment, alendronate effectively preserved bone mineral density into the second year of the trial.</p>
        <p>Mok et al conducted a study to examine the effects of denosumab or alendronate treatment on bone mineral density in patients receiving long-term prednisolone treatment.<xref ref-type="bibr" rid="article-17348.r14">[14]</xref> The study revealed that after 12 months of treatment, denosumab outperformed alendronate in increasing bone mineral density in the spine. However, both denosumab and alendronate also exhibited similar positive effects on bone mineral density in the hip and femoral neck.</p>
        <p>Brown et al investigated the impact of romosozumab compared to alendronate on lumbar spine bone mass and bone strength characteristics in postmenopausal women with osteoporosis.<xref ref-type="bibr" rid="article-17348.r15">[15]</xref> The study determined that romosozumab treatment resulted in superior bone mass and strength in the lumbar spine when compared to alendronate treatment.</p>
        <p>Martini et al examined the in vitro effects of alendronate on 3T3-L1 fibroblast-derived adipocytes, focusing on lipid characteristics and oxidative stress in mature adipocytes, as well as the inflammatory response of macrophages.<xref ref-type="bibr" rid="article-17348.r16">[16]</xref> The study revealed that alendronate reduced the differentiation of 3T3-L1 fibroblasts into adipocytes. Furthermore, it decreased hydrogen peroxide-induced lipid peroxidation and lowered triglyceride content. Alendronate also inhibited the activation of RAW 264.7 macrophages, shifting them away from the pro-inflammatory M1 type. These effects of alendronate can potentially decrease insulin resistance and adipocyte dysfunction.</p>
        <p>Viggers et al conducted a clinical study to examine the influence of alendronate treatment on the incidence of type 2 diabetes in patients and&#x000a0;whether alendronate had any effect on the development of this condition.<xref ref-type="bibr" rid="article-17348.r17">[17]</xref> The study revealed that alendronate therapy reduced the risk of developing type 2 diabetes.</p>
        <p>Ito et al studied the effects of alendronate on the bone mineral density of pregnant or lactating female mice.<xref ref-type="bibr" rid="article-17348.r18">[18]</xref> The conclusions derived from the animal studies research demonstrated that&#x000a0;temporary&#x000a0;alendronate treatment immediately before or after pregnancy or during lactation effectively mitigated bone loss, thereby indicating a protective effect.</p>
        <p>Zameer et al conducted research on mice exposed to d-galactose and aluminum chloride&#x02014;a combination known to induce neuropathologies and cognitive decline resembling Alzheimer disease.<xref ref-type="bibr" rid="article-17348.r19">[19]</xref> Oral administration of alendronate effectively reversed the neuropathologies and cognitive decline observed in the animal model for Alzheimer disease.</p>
      </sec>
      <sec id="article-17348.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Alendronate is available in various forms, including oral tablets in 5 mg, 10 mg, 35 mg, 40 mg, and 70 mg strengths; a 70 mg tablet for solution; and a 70 mg/75 mL oral solution.</p>
        <p>
<bold>Dosage&#x000a0;Regimens</bold>
</p>
        <p>For optimal effectiveness, alendronate should be taken in the morning with a full glass of water while standing or sitting upright and on an empty stomach. Individuals should maintain an upright position for 30 minutes after taking the medication to minimize the risk of adverse reactions and avoid chewing, sucking, or crushing the tablet.</p>
        <p>The dosing guidelines for alendronate are determined based on the patient's specific clinical indications, risk factors, and individual needs. Dosing guidelines are determined by the clinical indications, which are listed&#x000a0;below.</p>
        <p><bold>Postmenopausal women:</bold>&#x000a0;The recommended dosage options for postmenopausal women include an oral tablet of 5 mg&#x000a0;daily or 35 mg once weekly.</p>
        <p><bold>Glucocorticoid-induced osteoporosis:</bold>&#x000a0;The recommended dosages for individuals with glucocorticoid-induced osteoporosis are 5 mg oral tablet once daily or 10 mg oral tablet once daily for women not undergoing hormone replacement therapy.</p>
        <p><bold>Paget disease of bone:</bold> The recommended dosing regimen for individuals with this condition includes an oral tablet of 40 mg administered daily for a duration of 6 months.</p>
        <p><bold>Severe renal impairment:</bold>&#x000a0;Healthcare providers advise against using this medication for individuals with severe renal problems and suggest exploring alternative treatment options instead.</p>
        <p><bold>Low-risk of fracture:</bold>&#x000a0;In situations where there is a low risk of fracture, it is prudent to contemplate discontinuing the medication after 3 to 5 years of use.</p>
        <p><bold>Pediatric patients:</bold>&#x000a0;The safety and efficacy of this medication have not been established in pediatric populations.</p>
        <p><bold>Pregnancy and breastfeeding:&#x000a0;</bold>Alendronate was classified as a pregnancy category C drug in the previous FDA pregnancy category system. As the excretion of alendronate in the milk of lactating women is not well understood, it is recommended to exercise caution when using the drug during lactation.</p>
        <p>Individuals prescribed human parathyroid hormone should refrain from using alendronate simultaneously. This combination may diminish calcium-sparing effects, potentially resulting in unfavorable changes in serum calcium concentrations.</p>
        <p>Iles et al developed an experimental dosage form of alendronate nanoparticles, which resulted in fewer gastric lesions in Wistar rats and exhibited no toxicity in murine osteoblastic cells.<xref ref-type="bibr" rid="article-17348.r20">[20]</xref></p>
      </sec>
      <sec id="article-17348.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effects of alendronate&#x000a0;include transient hypocalcemia, transient hypophosphatemia, and GI symptoms, such as abdominal pain, heartburn, nausea, constipation, diarrhea, flatulence, and esophagitis. Other reported adverse events include myalgia, joint pain, headache, dizziness, peripheral edema, back pain, and weakness. Although infrequent, additionally reported adverse effects of alendronate encompass toxic epidermal necrolysis and oropharyngeal ulceration.<xref ref-type="bibr" rid="article-17348.r21">[21]</xref></p>
        <p>Post-marketing reports have indicated rare instances of osteonecrosis of the jaw, typically associated with tooth extraction or local infection with delayed healing. In addition, reports include esophageal erosions, esophagitis, esophageal ulcers, and hypersensitivity reactions.<xref ref-type="bibr" rid="article-17348.r22">[22]</xref></p>
        <p>Papamitsou et al conducted a study to investigate the effects of alendronate treatment on the stomach and liver of Wistar rats.<xref ref-type="bibr" rid="article-17348.r23">[23]</xref> The study revealed&#x000a0;microscopic inflammation of the stomach and mild hepatotoxicity.&#x000a0;</p>
        <p>Bautista-Villanueva et al reported a case of a patient who developed pustular skin reactions on both calves as a result of alendronate therapy.<xref ref-type="bibr" rid="article-17348.r24">[24]</xref> The male patient, aged 55, had a history of ulcerative colitis and osteoporosis and also experienced allergic reactions to mesalamine and golimumab.</p>
        <p>Zhang et al examined the effects of alendronate treatment on bone healing in 3-month-old female rats subjected to ovariectomy.<xref ref-type="bibr" rid="article-17348.r25">[25]</xref> The researchers developed an animal model with osteoporotic calvarial defects. Notably, alendronate treatment was found to impede the healing of the calvarial lesion in this animal model.</p>
        <p>Naganathar et al conducted a retrospective clinical study to investigate the effects of alendronate therapy on renal function in patients with osteoporosis, aged 65 and older, and experiencing reduced renal function (creatinine clearance &#x0003c;35 mL/min).<xref ref-type="bibr" rid="article-17348.r26">[26]</xref> The study indicated that alendronate therapy did not cause a significant reduction&#x000a0;in the patient's baseline renal function.</p>
      </sec>
      <sec id="article-17348.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to alendronate include patients with known hypersensitivity to the drug, as well as those with esophageal abnormalities, delayed esophageal emptying, or achalasia.&#x000a0;To mitigate the substantial risk of esophageal morbidity, it is advisable to refrain from administering the medication to patients who cannot maintain an upright sitting or standing position for a minimum of 30 minutes. In addition, alendronate should be avoided in patients with hypocalcemia.<xref ref-type="bibr" rid="article-17348.r21">[21]</xref></p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>Alendronate has no FDA-boxed warnings.</p>
      </sec>
      <sec id="article-17348.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Baseline concentrations of calcium and bone mineral density should be established before initiating alendronate therapy, with subsequent follow-up assessments at 6 to 12 months after commencing treatment. In cases with a recurring risk of hypocalcemia, it is essential to conduct baseline calcium measurements and maintain continuous monitoring. If hypocalcemia arises during treatment, the clinician should consider reducing the dose or discontinuing therapy. Furthermore, it is necessary to monitor magnesium and phosphorus levels at regular intervals.<xref ref-type="bibr" rid="article-17348.r27">[27]</xref></p>
        <p>Physicians should consider providing patients on alendronate therapy with intermittent breaks from the medication, also known as a drug holiday. The accumulation of alendronate&#x000a0;in the kidney allows for&#x000a0;persistent anti-fracture benefits even after the discontinuation of treatment. Current recommendations suggest tailoring the duration of the drug holiday based on individual patient needs. Typically, low-risk patients may benefit from a drug holiday lasting 3 to 5 years. Notably, alendronate is widely regarded as a highly safe medication, and the benefits of continued therapy often outweigh the benefits of a drug holiday.<xref ref-type="bibr" rid="article-17348.r28">[28]</xref></p>
      </sec>
      <sec id="article-17348.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>To date, there have been no reported toxicities associated&#x000a0;with the use of alendronate.&#x000a0;Although&#x000a0;certain post-marketing reports indicated an association with significant esophageal and gastric mucosal toxicity, subsequent studies have established that alendronate does not cause predictable mucosal damage when used as directed.<xref ref-type="bibr" rid="article-17348.r29">[29]</xref></p>
      </sec>
      <sec id="article-17348.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Alendronate is a commonly prescribed medication&#x000a0;for the management of osteoporosis and various other bone disorders, and it is often administered alongside vitamin D. A team of interprofessional healthcare providers comprising clinicians, nurses, and pharmacists must possess a comprehensive understanding of the therapeutic uses and potential adverse reactions of alendronate. The most concerning complication is osteonecrosis of the jaw, with the highest likelihood of occurrence following dental procedures.<xref ref-type="bibr" rid="article-17348.r30">[30]</xref> As a result, patients must be educated about the medication and the importance of consulting a healthcare provider before any oral cavity procedure.</p>
        <p>Pharmacists should take the initiative to educate patients about potential drug interactions involving alendronate. Furthermore, they should conduct a comprehensive medication reconciliation to identify and assess any possible drug interactions and promptly communicate any concerns to the patient's physician and nurse. All patients undergoing alendronate treatment necessitate vigilant monitoring for severe adverse effects. Nurses are responsible for overseeing&#x000a0;the medication, providing patient counseling, actively inquiring about potential adverse effects, and promptly informing the healthcare team of any concerns.<xref ref-type="bibr" rid="article-17348.r31">[31]</xref> The successful management of alendronate therapy necessitates effective interprofessional teamwork and coordination, featuring open communication channels and shared decision-making among patients and various team members, to achieve the best possible patient outcomes</p>
        <p>Chen et al conducted a population-based cohort study examining patient adherence to alendronate therapy to prevent a second hip fracture.<xref ref-type="bibr" rid="article-17348.r32">[32]</xref> The study indicated that having a medication possession ratio (MPR), which measures medication adherence, of 50% or higher for alendronate over a year reduces the risk of a second hip fracture.</p>
      </sec>
      <sec id="article-17348.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17348&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17348">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17348/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17348">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17348.s11">
        <title>References</title>
        <ref id="article-17348.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Le&#x000f3;n V&#x000e1;zquez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Herrero Hern&#x000e1;ndez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cuerpo Triguero</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;s Prado</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Cabello Ballesteros</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Prescription of alendronate and risedronate in men: off-label use in a health area.</article-title>
            <source>Reumatol Clin</source>
            <year>2015</year>
            <season>Mar-Apr</season>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>64</fpage>
            <page-range>64-7</page-range>
            <pub-id pub-id-type="pmid">25107345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Compston</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Osteoporosis in inflammatory bowel disease.</article-title>
            <source>Gut</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-4</page-range>
            <pub-id pub-id-type="pmid">12477761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papaioannou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Freitag</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ioannidis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Webber</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berthiaume</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rabin</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Paterson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jeanneret</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matouk</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Villeneuve</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nixon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adachi</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial).</article-title>
            <source>Chest</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>134</volume>
            <issue>4</issue>
            <fpage>794</fpage>
            <page-range>794-800</page-range>
            <pub-id pub-id-type="pmid">18641106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aris</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Lester</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Caminiti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blackwood</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Hensler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lark</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Hecker</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Renner</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Guillen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Neuringer</surname>
                <given-names>IP</given-names>
              </name>
              <name>
                <surname>Chalermskulrat</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ontjes</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of alendronate in adults with cystic fibrosis with low bone density.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2004</year>
            <month>Jan</month>
            <day>01</day>
            <volume>169</volume>
            <issue>1</issue>
            <fpage>77</fpage>
            <page-range>77-82</page-range>
            <pub-id pub-id-type="pmid">14563654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Delmas</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Meunier</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.</article-title>
            <source>Lancet</source>
            <year>1994</year>
            <month>Apr</month>
            <day>16</day>
            <volume>343</volume>
            <issue>8903</issue>
            <fpage>953</fpage>
            <page-range>953-4</page-range>
            <pub-id pub-id-type="pmid">7909013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biermasz</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Hamdy</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Roelfsema</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>86</volume>
            <issue>7</issue>
            <fpage>3079</fpage>
            <page-range>3079-85</page-range>
            <pub-id pub-id-type="pmid">11443170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diskin</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Stokes</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Dansby</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Radcliff</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>TB</given-names>
              </name>
            </person-group>
            <article-title>Malignancy-related hypercalcemia developing on a bisphosphonate but responding to calcitonin.</article-title>
            <source>Clin Lung Cancer</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>434</fpage>
            <page-range>434-5</page-range>
            <pub-id pub-id-type="pmid">17681097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirrakhimov</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Hypercalcemia of Malignancy: An Update on Pathogenesis and Management.</article-title>
            <source>N Am J Med Sci</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>7</volume>
            <issue>11</issue>
            <fpage>483</fpage>
            <page-range>483-93</page-range>
            <pub-id pub-id-type="pmid">26713296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shimon</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Eshed</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Doolman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sela</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Karasik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vered</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Alendronate for osteoporosis in men with androgen-repleted hypogonadism.</article-title>
            <source>Osteoporos Int</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>1591</fpage>
            <page-range>1591-6</page-range>
            <pub-id pub-id-type="pmid">16362147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eghbali-Fatourechi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonate therapy in pediatric patients.</article-title>
            <source>J Diabetes Metab Disord</source>
            <year>2014</year>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>109</fpage>
            <pub-id pub-id-type="pmid">25551100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Alendronate promotes the gene expression of extracellular matrix mediated by SP-1/SOX-9.</article-title>
            <source>Hum Exp Toxicol</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>40</volume>
            <issue>7</issue>
            <fpage>1173</fpage>
            <page-range>1173-1182</page-range>
            <pub-id pub-id-type="pmid">33522294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vrahnas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Buenzli</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Pennypacker</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Tobin</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bambery</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Duong</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Sims</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Differing Effects of Parathyroid Hormone, Alendronate, and Odanacatib on Bone Formation and on the Mineralization Process in Intracortical and Endocortical Bone of Ovariectomized Rabbits.</article-title>
            <source>Calcif Tissue Int</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>103</volume>
            <issue>6</issue>
            <fpage>625</fpage>
            <page-range>625-637</page-range>
            <pub-id pub-id-type="pmid">30019315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kendler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chines</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ebeling</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>McClung</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stad</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Bone Mineral Density After Transitioning From Denosumab to Alendronate.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2020</year>
            <month>Mar</month>
            <day>01</day>
            <volume>105</volume>
            <issue>3</issue>
            <fpage>e255</fpage>
            <page-range>e255-64</page-range>
            <pub-id pub-id-type="pmid">31665314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mok</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>SMT</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SPL</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial.</article-title>
            <source>Bone</source>
            <year>2021</year>
            <month>May</month>
            <volume>146</volume>
            <fpage>115902</fpage>
            <pub-id pub-id-type="pmid">33631355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Engelke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Keaveny</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Chines</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chapurlat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Foldes</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Nogues</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Civitelli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Villiers</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Massari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zerbini</surname>
                <given-names>CAF</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Oates</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Recknor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Libanati</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial.</article-title>
            <source>J Bone Miner Res</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>36</volume>
            <issue>11</issue>
            <fpage>2139</fpage>
            <page-range>2139-2152</page-range>
            <pub-id pub-id-type="pmid">34190361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Malvicini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pacienza</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yannarelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Del C Vila</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Alendronate inhibits triglyceride accumulation and oxidative stress in adipocytes and the inflammatory response of macrophages which are associated with adipose tissue dysfunction.</article-title>
            <source>J Physiol Biochem</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>77</volume>
            <issue>4</issue>
            <fpage>601</fpage>
            <page-range>601-611</page-range>
            <pub-id pub-id-type="pmid">34302624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viggers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Al-Mashhadi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Starup-Linde</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vestergaard</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>771426</fpage>
            <pub-id pub-id-type="pmid">34867816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ito</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Soma</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Transient alendronate administration to pregnant or lactating mothers prevents bone loss in mice without adverse effects on offspring.</article-title>
            <source>Bone</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>153</volume>
            <fpage>116133</fpage>
            <pub-id pub-id-type="pmid">34329815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zameer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vohora</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kalam Najmi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Akhtar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Alendronate reduces the cognitive and neurological disturbances induced by combined doses of d-galactose and aluminum chloride in mice.</article-title>
            <source>J Appl Toxicol</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>41</volume>
            <issue>11</issue>
            <fpage>1779</fpage>
            <page-range>1779-1793</page-range>
            <pub-id pub-id-type="pmid">33694194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iles</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ribeiro de S&#x000e1; Guimar&#x000e3;es Nol&#x000ea;to</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dourado</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>de Oliveira Silva Ribeiro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>de Ara&#x000fa;jo</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>de Oliveira</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>JMT</given-names>
              </name>
              <name>
                <surname>Barros</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Sousa</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>de Jesus Oliveira</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>da Silva Martins</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Oliveira Viana Veras</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Carvalho Leit&#x000e3;o</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>de Souza de Almeida Leite</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Medeiros</surname>
                <given-names>JVR</given-names>
              </name>
            </person-group>
            <article-title>Alendronate sodium-polymeric nanoparticles display low toxicity in gastric mucosal of rats and Ofcol II cells.</article-title>
            <source>NanoImpact</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>24</volume>
            <fpage>100355</fpage>
            <pub-id pub-id-type="pmid">35559814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Musette</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rizzoli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cacoub</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brandi</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Reginster</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous side effects of antiosteoporosis treatments.</article-title>
            <source>Ther Adv Musculoskelet Dis</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-41</page-range>
            <pub-id pub-id-type="pmid">22870464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Groen</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Lubbe</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Daifotis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stephenson</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Freedholm</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pryor-Tillotson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seleznick</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Pinkas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Esophagitis associated with the use of alendronate.</article-title>
            <source>N Engl J Med</source>
            <year>1996</year>
            <month>Oct</month>
            <day>03</day>
            <volume>335</volume>
            <issue>14</issue>
            <fpage>1016</fpage>
            <page-range>1016-21</page-range>
            <pub-id pub-id-type="pmid">8793925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papamitsou</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sotiriou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Papakoulas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Toskas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kamperis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Karachrysafi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dietrich</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Lialiaris</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sioga</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Alendronate effect in esophagus, stomach and liver: an animal based pathological study.</article-title>
            <source>Histol Histopathol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>417</fpage>
            <page-range>417-422</page-range>
            <pub-id pub-id-type="pmid">31502656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bautista-Villanueva</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Galleani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barranco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bell&#x000f3;n</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Blanco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Moguel</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Acute Localized Exanthematous Pustulosis Due to Alendronate.</article-title>
            <source>J Investig Allergol Clin Immunol</source>
            <year>2021</year>
            <month>Feb</month>
            <day>21</day>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-70</page-range>
            <pub-id pub-id-type="pmid">34045177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Long-term pretreatment with alendronate inhibits calvarial defect healing in an osteoporotic rat model.</article-title>
            <source>J Bone Miner Metab</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>925</fpage>
            <page-range>925-933</page-range>
            <pub-id pub-id-type="pmid">34091742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naganathar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yau</surname>
                <given-names>W-</given-names>
              </name>
              <name>
                <surname>Mok</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>ZYF</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>STH</given-names>
              </name>
            </person-group>
            <article-title>Alendronate use in older patients with reduced renal function: challenges and opportunities in clinical practice.</article-title>
            <source>Osteoporos Int</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>10</issue>
            <fpage>1981</fpage>
            <page-range>1981-1988</page-range>
            <pub-id pub-id-type="pmid">33721033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braga de Castro Machado</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hannon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eastell</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Monitoring alendronate therapy for osteoporosis.</article-title>
            <source>J Bone Miner Res</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>602</fpage>
            <page-range>602-8</page-range>
            <pub-id pub-id-type="pmid">10234582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diab</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>NB</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonate drug holiday: who, when and how long.</article-title>
            <source>Ther Adv Musculoskelet Dis</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>107</fpage>
            <page-range>107-11</page-range>
            <pub-id pub-id-type="pmid">23858334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lowe</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Depew</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Vanner</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Paterson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Meddings</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Upper gastrointestinal toxicity of alendronate.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>95</volume>
            <issue>3</issue>
            <fpage>634</fpage>
            <page-range>634-40</page-range>
            <pub-id pub-id-type="pmid">10710050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cummings</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Santora</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>RGG</given-names>
              </name>
            </person-group>
            <article-title>History of alendronate.</article-title>
            <source>Bone</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>137</volume>
            <fpage>115411</fpage>
            <pub-id pub-id-type="pmid">32437874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carter</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prevention of Glucocorticoid-Induced Osteoporosis: Clinical audit to evaluate the implementation of National Osteoporosis Guideline Group 2017 guidelines in a primary care setting.</article-title>
            <source>J Clin Densitom</source>
            <year>2019</year>
            <season>Jan-Mar</season>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-30</page-range>
            <pub-id pub-id-type="pmid">29729949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17348.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Kung</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan.</article-title>
            <source>Osteoporos Int</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>8</issue>
            <fpage>1555</fpage>
            <page-range>1555-1563</page-range>
            <pub-id pub-id-type="pmid">32221674</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
